Efficacy and Safety of Simenafil in Men with Erectile Dysfunction: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Parallel-Group, Phase 2 Trial

Phase 2 RCT of 255 men finds simenafil (5–20 mg) improves IIEF-EF scores ~9 points over placebo, but 20 mg hits 62% adverse event rate with no clear efficacy advantage over 5 mg

Journal: The Journal of Sexual Medicine | Published: 2026-05-09 | Type: Phase 2 RCT, Multicenter | PMID: 42114123 Authors: Yang Yuzhuo et al., multiple Chinese academic medical centers; Juan Jiaxiang and Duan Huaqing (Vigonvita Life Sciences Co., Ltd., Suzhou) Funding/COI: Funded by Vigonvita Life Sciences Co., Ltd. — the drug's manufacturer. Two authors carry Vigonvita institutional affiliations. The PubMed record lists COI as "not listed," which conflicts with those affiliations.

Summary

Simenafil is a new selective PDE5 inhibitor developed in China for on-demand erectile dysfunction treatment. This phase 2 RCT randomized 255 men across multiple Chinese centers to placebo or one of three fixed doses (5, 10, or 20 mg) for 8 weeks. All three doses outperformed placebo on validated erectile function measures, but the dose-response relationship was flat — 5 mg performed as well as 20 mg — while adverse event rates climbed steeply with dose.

Claims

• IIEF-EF score improvement from baseline: 9.7 (5 mg), 9.2 (10 mg), 9.5 (20 mg) vs. 5.5 (placebo); all p < 0.001
• SEP Q2 penetration success rate: 36.1% (5 mg), 30.8% (10 mg), 33.1% (20 mg) vs. 19.6% (placebo); p < 0.01
• SEP Q3 sustained intercourse success rate: 56.0% (5 mg), 51.1% (10 mg), 51.1% (20 mg) vs. 31.0% (placebo); p < 0.001
• Adverse event rates: 36.5% (placebo), 44.3% (5 mg), 45.9% (10 mg), 61.7% (20 mg) — described as mostly mild to moderate
• n = 255 (~64 per arm); duration: 8 weeks

Study Quality

This is a properly structured phase 2 RCT: randomized, double-blind, placebo-controlled, multicenter, using the IIEF-EF and SEP diary as pre-specified primary endpoints — both validated, widely accepted instruments in ED research. The four-arm design with three dose levels is appropriate for a dose-finding objective.

The trial was designed to establish dose range, not to demonstrate non-inferiority or superiority to existing PDE5 inhibitors. With roughly 64 patients per arm over 8 weeks, this is underpowered for long-term safety assessment and provides no head-to-head comparison against sildenafil, tadalafil, or other approved agents. The Chinese-center-only population limits generalizability. Critically, the manufacturer funded the study and placed two employees as co-authors — an arrangement with well-documented associations with favorable reporting bias.

Red Flags

• Manufacturer funding with insider authors: Two authors are Vigonvita employees. The PubMed COI field reads "not listed" despite their affiliations appearing in the author list — a paperwork contradiction that should have been caught at peer review.
• Flat, non-monotonic dose-response: 5 mg outperformed both 10 mg and 20 mg on the IIEF-EF primary endpoint (9.7 vs. 9.2 vs. 9.5). This pattern does not support a clean efficacy argument for higher doses and warrants pharmacological explanation.
• High adverse event rate at 20 mg: 61.7% of patients in the 20 mg arm reported adverse drug reactions — nearly double the placebo rate (36.5%). Characterizing this as "mild to moderate" is noted, but the magnitude demands scrutiny in a phase 3 context.
• No active comparator: Demonstrating superiority to placebo is necessary but insufficient for clinical positioning. A comparison to an approved PDE5i is absent.
• Short duration: 8 weeks captures neither long-term efficacy maintenance nor delayed adverse events.
• Unusual first-author affiliation: Yang Yuzhuo is listed under the Department of Obstetrics and Gynecology at Peking University First Hospital — an unexpected home department for an erectile dysfunction trial's lead investigator.

Strengths

• Gold-standard design: double-blind, randomized, placebo-controlled, multicenter
• Pre-specified primary endpoints using validated instruments (IIEF-EF, SEP Q2/Q3)
• Phase 2 scope is appropriate — this is a dose-ranging study, not a registration trial
• All three doses showed statistically significant improvement across all three primary endpoints
• Adverse event profile is mechanistically consistent with PDE5 inhibitor pharmacology

Verdict

A competent phase 2 trial doing exactly what phase 2 trials are designed to do: confirming a biological signal and narrowing a dose range. Simenafil demonstrably outperforms placebo on validated endpoints. But the flat dose-response curve, the steep adverse event climb at 20 mg, the absence of any active comparator, and a manufacturer-authored design mean this paper answers only the narrowest possible question — "does it beat a sugar pill?" A phase 3 trial against an established PDE5 inhibitor, in a broader and more diverse population, over a longer horizon, would be needed to tell us anything clinically meaningful about where simenafil belongs. The undisclosed COI situation is a structural problem that reviewers should have flagged. Watch for phase 3 data; don't cite this as evidence of clinical utility.